CSIMarket
 


Alexion Pharmaceuticals Inc   (ALXN)
Other Ticker:  
 
 

ALXN's Capital Expenditures Growth by Quarter and Year

Alexion Pharmaceuticals Inc 's Capital Expenditures results by quarter and year




ALXN Capital Expenditures (in millions $) FY 2021 FY 2020 FY 2019 FY 2018
IV Quarter December - 77.50 30.00 42.40
III Quarter September - 10.80 49.90 41.20
II Quarter June - 6.20 46.80 62.80
I Quarter March 130.20 12.20 44.00 66.60
FY   130.20 106.70 170.70 213.00



ALXN Capital Expenditures first quarter 2021 Y/Y Growth Comment
Alexion Pharmaceuticals Inc showed record Capital Expenditures surge in the first quarter 2021 with 967.21% from the first quarter 2021 2020, to $ 130.20 millions.

Looking into first quarter 2021 results within Major Pharmaceutical Preparations industry 33 other companies have achieved higher Capital Expenditures growth. While Alexion Pharmaceuticals Inc ' s Capital Expenditures doubling of 967.21% ranks overall at the positon no. 116 in the first quarter 2021.




ALXN Capital Expenditures ( Y/Y Growth %) 2021
2020 2019 2018
IV Quarter December - 158.33 % -29.25 % -51.98 %
III Quarter September - -78.36 % 21.12 % -56.17 %
II Quarter June - -86.75 % -25.48 % -37.2 %
I Quarter March 967.21 % -72.27 % -33.93 % -11.2 %
FY   - -37.49 % -19.86 % -40.39 %

Financial Statements
Alexion Pharmaceuticals Inc 's first quarter 2021 Capital Expenditures $ 130.20 millions ALXN's Income Statement
Alexion Pharmaceuticals Inc 's first quarter 2020 Capital Expenditures $ 12.20 millions Quarterly ALXN's Income Statement
New: More ALXN's historic Capital Expenditures Growth >>


ALXN Capital Expenditures (Quarter on Quarter Growth %)

2021
2020 2019 2018
IV Quarter December - 617.59 % -39.88 % 2.91 %
III Quarter September - 74.19 % 6.62 % -34.39 %
II Quarter June - -49.18 % 6.36 % -5.71 %
I Quarter March 68 % -59.33 % 3.77 % -24.58 %
FY (Year on Year)   - -37.49 % -19.86 % -40.39 %




Capital Expenditures first quarter 2021 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #34
Healthcare Sector #55
Overall #116

Capital Expenditures Y/Y Growth Statistics
High Average Low
967.21 % 100.13 % -86.75 %
(Mar 31 2021)   (Jun 30 2020)
Capital Expenditures first quarter 2021 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #34
Healthcare Sector #55
Overall #116
Capital Expenditures Y/Y Growth Statistics
High Average Low
967.21 % 100.13 % -86.75 %
(Mar 31 2021)   (Jun 30 2020)

Capital Expenditures by Quarter for the Fiscal Years 2018, 2019, 2020, 2021

Alexion Pharmaceuticals Inc 's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
617.59 % 32.78 % -59.33 %
(Dec 31 2020)  


ALXN's I. Quarter Q/Q Capital Expenditures Comment
Alexion Pharmaceuticals Inc achieved in the I. Quarter 2021 above company average sequential Capital Expenditures jump of 68%, to $ 130.20 millions, from $77.50 millions in the fourth quarter.

Within Major Pharmaceutical Preparations industry 62 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Alexion Pharmaceuticals Inc 's Capital Expenditures growth quarter on quarter, overall rank is 538.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #63
Healthcare Sector #127
Overall #538
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #63
Healthcare Sector #127
Overall #538
Capital Expenditures Q/Q Growth Statistics
High Average Low
617.59 % 32.78 % -59.33 %
(Dec 31 2020)  


ALXN's I. Quarter Q/Q Capital Expenditures Comment
Alexion Pharmaceuticals Inc achieved in the I. Quarter 2021 above company average sequential Capital Expenditures jump of 68%, to $ 130.20 millions, from $77.50 millions in the fourth quarter.

Within Major Pharmaceutical Preparations industry 62 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Alexion Pharmaceuticals Inc 's Capital Expenditures growth quarter on quarter, overall rank is 538.


Alexion Pharmaceuticals Inc 's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Mar 31 2021)
12 Months Ending
(Dec 31 2020)
12 Months Ending
(Sep 30 2020)
12 Months Ending
(Jun 30 2020)
12 Months Ending
(Mar 31 2020)
Cumulative Capital Expenditures 12 Months Ending $ 224.70 $ 106.70 $ 59.20 $ 98.30 $ 138.90
Y / Y Capital Expenditures Growth (TTM) 61.77 % -37.49 % -67.67 % -43.64 % -27.05 %
Year on Year Capital Expenditures Growth Overall Ranking # 1856 # 300 # 2712 # 2295 # 2333
Seqeuential Capital Expenditures Change (TTM) 110.59 % 80.24 % -39.78 % -29.23 % -18.63 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 1653 # 160 # 2903 # 382 # 1429




Cumulative Capital Expenditures growth Comment
Alexion Pharmaceuticals Inc saw improvement in Capital Expenditures growth trend, posting cumulative 12 months Capital Expenditures growth of 61.77% year on year, to $ 225 millions if the fiscal year would have ended in Mar 31 2021.
Alexion Pharmaceuticals Inc 's trailing twelve months Capital Expenditures growth was higher than company's average 51.34% and higher than -37.49% growth in Dec 31 2020.
The growth was much higher from twelve months ended Dec 31 2020 clinched at 110.59 % rise from $106.7 millions in twelve months ending a quarter before.

In the Healthcare sector 323 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 300 to 1856.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
365.92 %
51.34 %
-67.67 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 113
Healthcare Sector # 324
Overall # 1856

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
365.92 %
51.34 %
-67.67 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 113
Sector # 304
S&P 500 # 1653
Cumulative Capital Expenditures growth Comment
Alexion Pharmaceuticals Inc saw improvement in Capital Expenditures growth trend, posting cumulative 12 months Capital Expenditures growth of 61.77% year on year, to $ 225 millions if the fiscal year would have ended in Mar 31 2021.
Alexion Pharmaceuticals Inc 's trailing twelve months Capital Expenditures growth was higher than company's average 51.34% and higher than -37.49% growth in Dec 31 2020.
The progress was much stronger sequentially exhibited at 110.59 % increase from $106.7 millions in the period from Dec 31 2020 to Mar 31 2020.

In the Healthcare sector 323 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 300 to 1856.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
365.92 %
51.34 %
-67.67 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 113
Healthcare Sector # 324
Overall # 1856

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
365.92 %
51.34 %
-67.67 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 113
Sector # 304
S&P 500 # 1653




Other Capital Expenditures Growth
Major Pharmaceutical Preparations Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
ALXN's Capital Expenditures Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for ALXN's Competitors
Capital Expenditures Growth for Alexion Pharmaceuticals Inc 's Suppliers
Capital Expenditures Growth for ALXN's Customers

You may also want to know
ALXN's Annual Growth Rates ALXN's Profitability Ratios ALXN's Asset Turnover Ratio ALXN's Dividend Growth
ALXN's Roe ALXN's Valuation Ratios ALXN's Financial Strength Ratios ALXN's Dividend Payout Ratio
ALXN's Roa ALXN's Inventory Turnover Ratio ALXN's Growth Rates ALXN's Dividend Comparisons



Companies with similar Capital Expenditures jump for the quarter ending Mar 31 2021 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Mar 31 2021
Arcus Biosciences Inc 1,642.11%$ 1,642.105 millions
Iovance Biotherapeutics Inc 1,580.53%$ 1,580.534 millions
Xeris Biopharma Holdings Inc 1,550.00%$ 1,550.000 millions
Enveric Biosciences Inc 1,456.23%$ 1,456.232 millions
Y mabs Therapeutics inc 1,438.46%$ 1,438.462 millions
Imunon Inc 1,437.30%$ 1,437.304 millions
Fulgent Genetics Inc 1,343.72%$ 1,343.719 millions
Zentalis Pharmaceuticals Inc 1,306.45%$ 1,306.452 millions
Arcutis Biotherapeutics Inc 1,251.22%$ 1,251.220 millions
Quidelortho Corp1,230.57%$ 1,230.574 millions
Passage Bio inc 1,214.14%$ 1,214.141 millions
Otonomy Inc 1,200.00%$ 1,200.000 millions
Constellation Pharmaceuticals Inc1,189.47%$ 1,189.474 millions
Chemocentryx Inc.1,153.46%$ 1,153.456 millions
Chinook Therapeutics Inc 1,137.50%$ 1,137.500 millions
Predictive Oncology Inc 1,109.23%$ 1,109.231 millions
Nighthawk Biosciences inc 1,086.30%$ 1,086.296 millions
Biolife Solutions Inc 1,078.08%$ 1,078.082 millions
Aytu Biopharma Inc 1,040.65%$ 1,040.646 millions
Scholar Rock Holding Corp1,006.22%$ 1,006.220 millions
Chimerix Inc 971.43%$ 971.429 millions
Alexion Pharmaceuticals Inc 967.21%$ 967.213 millions
Ibio inc 959.38%$ 959.375 millions
Neurogene Inc 917.76%$ 917.757 millions
Lftd Partners Inc 882.94%$ 882.940 millions
Immunovant Inc 850.00%$ 850.000 millions
Sintx Technologies Inc 809.52%$ 809.524 millions
Imac Holdings Inc 808.04%$ 808.035 millions
Harpoon Therapeutics Inc 800.00%$ 800.000 millions
Meridian Bioscience Inc 720.37%$ 720.366 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com